Pharmacokinetic Characterization of Three Doses of Tipranavir Boosted with Ritonavir on Highly Active Antiretroviral Therapy in Treatment-Experienced HIV-1 Patients

REFERENCES

• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1–139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Accessed September 3,2009.
   Google Scholar
• Hammer SM, Eron JJ, Reiss R, et al. Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the Interna-tional AIDS Society-USA Panel. JAMA. 2008;300:555–570.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Wegner SA, Milazzo MJ, et al. Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS. 2006;20:1531–1538.
   PubMed Web of Science ®Google Scholar
• Hoen B, Cooper DA, Lampe FC, et al. Predictors of viro-logical outcome and safety in primary HIV Type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis. 2007;45:381–390.
   PubMed Web of Science ®Google Scholar
• Chrusciel RA, Strohbach JW. Non-peptidic HIV protease inhibitors. Curr Top Med Chem. 2004;4:1097–1114.
   PubMed Web of Science ®Google Scholar
• Mehandru S, Markowitz M. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection. Expert Opin Inyestig Drugs. 2003;12:1821–1828.
   PubMed Web of Science ®Google Scholar
• Back NK, van Wijk A, Remmerswaal D, et al. In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS 2000;14: 101–102.
   PubMed Web of Science ®Google Scholar
• Larder BA, Hertogs K, Bloor S, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS. 2000;14:1943–1948.
   PubMed Web of Science ®Google Scholar
• Gathe JC, Pierone G, Piliero P, et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treat-ment-experienced HIV type 1-infected patients. AIDS Res Hum Retroyiruses 2007;23:216–223.
   PubMed Web of Science ®Google Scholar
• Khaliq Y, Gallicano K, Tisdale C, Carignan G, Cooper C, McCarthy A. Pharmacokinetic interaction between meflo-quine and ritonavir in healthy volunteers. Br J Clin Pharma-co/. 200151: 591–600
   Google Scholar
• Koudriakova T, Latsimirskaia I, Utkin I, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos. 1998;26:552–561.
   PubMed Web of Science ®Google Scholar
• Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibi-tion of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos. 1999;27:902–908.
   PubMed Web of Science ®Google Scholar
• MacGregor TR, Sabo JP, Norris SH, Johnson P, Galitz L, McCallister S. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritona-vir in healthy volunteers. HIV Clin Trials. 2004;5:371–382.
   PubMed Web of Science ®Google Scholar
• McCallister S, Valdez H, Curry K, et al. A 14-day dose-response study of the efficacy, safety, and pharmacoki-netics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35:376–382.
   PubMed Web of Science ®Google Scholar
• Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006;43:1337–1346.
   PubMed Web of Science ®Google Scholar
• Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tip-ranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006;43:1347–1356.
   PubMed Web of Science ®Google Scholar
• Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an opti-mised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Inter-vention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006;368: 466–475.
   PubMed Web of Science ®Google Scholar
• Chen L, Sabo JP, Philip E, et al. Steady state disposition of the nonpeptidic protease inhibitor tipranavir when coad-ministered with ritonavir. Antimicrob Agents Chemother. 2007;51:2436–2444.
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Acosta EP, Cheng H, et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS. 2000;14:2495–2501.
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med . 2001;344:984–996.
   PubMed Web of Science ®Google Scholar
• Division of AIDS table for grading the severity of adult and pediatric adverse events, version 1.0. December 28, 2004; 1–20. Available at: http://www.ucdmc.ucdavis.edu/clinicaltrials/documents/DAIDS_AE_GradingTable_Final-Dec2004.pdf Accessed November 11,2009.
   Google Scholar
• Cato A, Qian J, Hsu A, Levy B, Leonard J, Granneman R. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimi-crob Agents Chemother. 1998;42:1788–1793.
   PubMed Web of Science ®Google Scholar
• Cato A, Qian J, Hsu A, et al. Pharmacokinetic interaction between ritonavir and didanosine when administered con-currently to HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:466–472.
   PubMedGoogle Scholar
• Veal GJ, Back DJ. Metabolism of zidovudine. Gen Pharma-co/. 1995;26:1469–1475.
   PubMedGoogle Scholar
• Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: Implications for drug interactions. Ann Pharma-cother 2008;42:1048–1059.
   PubMed Web of Science ®Google Scholar
• Stein DS, Moore KH. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmaco-therapy. 2001;21:11–34.
   Web of Science ®Google Scholar
• Piliero, PJ. Pharmacokinetic properties of nucleoside/ nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2004;37:S2–S12.
   PubMed Web of Science ®Google Scholar
• Sommadossi JP, Valentin MA, Zhou XJ, et al. Intracellular phos-phorylation of stavudine (d4T) and lamivudine (3TC) correlates with their antiviral activity in naive and zidovudine (ZDV)-experi-enced HIV-infected patients. Presented at: Fifth Conference on Retroviruses and Opportunistic Infections; Chicago; February 1998. Abstract 362. Available at: http://www.hivresistanceweb.com/protected/biblio/98-sommadossi.shtml.
   Google Scholar
• Moore JD, Valette G, Darque A, Zhou X-J, Sommadossi J-P. Simultaneous quantitation of the 5'-triphosphate metabo-lites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrom-etry. J Am Soc Mass Spectrometry 2000;11:1134–1143.
   PubMed Web of Science ®Google Scholar